Anavex Life Sciences Corp (AVXL)

[ALP7]

Such a bizarre statement from someone claiming extensive experience in this field. When Big Pharma has a blockbuster drug that is facing the patent expiration cliff, they are under pressure to get deals done to keep their pipeline robust. That is the opposite of being risk adverse.

"Biotech investors might be longing for an uptick in M&A to lift spirits, but at least licensing deal activity remains healthy. More than $9bn in up-front fees has changed hands so far this year, and 2021 is not yet over." https://www.evaluate.com/vantage/articles/analysis-insights/licensing-deals-rack-2021

"2021 was another banner year for dealmaking in the life sciences
sector. Biopharma therapeutics and discovery platform companies
led the way in licensing and venture capital attraction" Note slide 8 of this JPMorgan presentation: https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/pdf-dealforma-2022-Annual-outlook-final-ada.pdf

More good info here: https://www.alacrita.com/whitepapers/pharma-licensing-trends-and-wishlist